Rheumatology最新文献

{"title":"Comment on: Arterial cardiovascular outcomes and venous thromboembolism in patients with primary Sjögren's syndrome: a Danish cohort study.","authors":"Maria I Zervou, George N Goulielmos","doi":"10.1093/rheumatology/keaf365","DOIUrl":"10.1093/rheumatology/keaf365","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"5576-5577"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baricitinib in rheumatoid arthritis-interstitial lung disease: a literature review and national multicentre study of 72 patients.","authors":"Ana Serrano-Combarro, Belén Atienza-Mateo, Adrián Martín-Gutiérrez, Jesús Loarce-Martos, César Antonio Egües Dubuc, Marta Pastor Mena, Rafael B Melero-Gonzalez, María Martín López, Natalia Mena Vázquez, Carmen Carrasco-Cubero, Carolina Pérez García, Andrea García Valle, Gema Bonilla, Juan María Blanco Madrigal, Uxue Astigarraga-Urquia, Nuria Vegas Revenga, Lorena Pérez Albadalejo, Rafaela Ortega Castro, Deseada Palma-Sánchez, Ana María Fernández Ortiz, Patricia López Viejo, María López Lasanta, Marta Garijo Bufort, Ivette Casafont Solé, José Ramón Lamua-Riazuelo, Ignacio Braña Abascal, Virginia Ruiz-Esquide, Evelin Cecilia Cervantes Pérez, Bryan-Josué Flores Robles, María Paz Martínez-Vidal, Juan Moreno Morales, Ana Urruticoechea-Arana, José Rosas, Delia Fernández-Lozano, David Castro Corredor, Iván Ferraz-Amaro, Santos Castañeda, Ricardo Blanco","doi":"10.1093/rheumatology/keaf314","DOIUrl":"10.1093/rheumatology/keaf314","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to assess the effectiveness and safety of baricitinib (BARI) in interstitial lung disease associated with RA (RA-ILD) in clinical practice.</p><p><strong>Methods: </strong>: This was a national multicentre retrospective study of 72 RA-ILD patients treated with BARI. We analysed the following outcomes at baseline and at 3, 6, 12, 18 and 24 months, and at last follow-up: (i) dyspnea (modified Medical Research Council scale), (ii) forced vital capacity (FVC), (iii) diffusing capacity of the lungs for carbon monoxide (DLCO), (iv) chest high-resolution CT (HRCT), (v) arthritis activity (DAS28-ESR), and (vi) CS-sparing effect. Additionally, we analysed the safety data and performed a literature review up to December 2023.</p><p><strong>Results: </strong>We included 72 patients (52 women; mean (s.d.) age 68 (10) years). All patients had received DMARDs. The median [interquartile range (IQR)] ILD duration up to BARI initiation was 25 [13-63] months. The most frequent ILD patterns were usual interstitial pneumonia (n = 33; 49%) and non-specific interstitial pneumonia (n = 22; 32%). BARI was used in monotherapy in 43 (60%) patients and combined with conventional synthetic DMARDs in 29 (40%). Mean (s.d.) baseline values of FVC and DLCO (% predicted) were 86 (28) and 69 (20), respectively. After a median [IQR] follow-up of 32 [13-65] months, dyspnea, FVC, DLCO and HRCT improved or stabilized in 90%, 88%, 65% and 72%, respectively. The mean DAS28-ESR improved from 4.29 to 2.99, and the median prednisone dose was reduced from 5 to 2.5 mg/day. Relevant adverse events were uncommon.</p><p><strong>Conclusion: </strong>BARI may be a useful and safe alternative in both pulmonary and joint disease in RA-ILD patients, even in refractory cases.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"5471-5480"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: NETs in the spotlight: exploring NETosis markers for tracking disease activity in IgA vasculitis.","authors":"Sujoy Khan","doi":"10.1093/rheumatology/keaf401","DOIUrl":"10.1093/rheumatology/keaf401","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"5581"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144718267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Risk factors of digital gangrene secondary to systemic lupus erythematosus flare: real-world data from 2014 to 2022.","authors":"Duygu Tecer, Sedat Yilmaz","doi":"10.1093/rheumatology/keaf378","DOIUrl":"10.1093/rheumatology/keaf378","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"5578-5579"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus serology: off target but still relevant to the treat-to-target strategy in systemic lupus erythematosus.","authors":"Matteo Piga","doi":"10.1093/rheumatology/keaf332","DOIUrl":"10.1093/rheumatology/keaf332","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"5201-5203"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort.","authors":"Stefano Di Donato, John D Pauling, Sheila Ramjug, Yannick Allanore, Edward B Jude, Marie-Elise Truchetet, Paolo Airò, Lidia P Ananyeva, Andra Balanescu, Gonçalo Boleto, Francesco Paolo Cantatore, Patricia E Carreira, Carolina de Souza Müller, Masataka Kuwana, Gianluca Moroncini, Marco Di Battista, Luc Mouthon, Madelon C Vonk, Elisabetta Zanatta, Marco Matucci-Cerinic, Francesco Del Galdo, Michael Hughes","doi":"10.1093/rheumatology/keaf290","DOIUrl":"10.1093/rheumatology/keaf290","url":null,"abstract":"<p><strong>Objectives: </strong>Systemic sclerosis (SSc) is characterized by widespread vascular damage resulting in digital and systemic vasculopathic sequelae. Although there are effective treatments available, vascular disease remains a significant cause of morbidity and mortality in SSc. Our aim was to describe patterns of vascular medication use in SSc, including examination for potential changes over time.</p><p><strong>Methods: </strong>A cross-sectional study of SSc patients enrolled in the EUSTAR database meeting 2013 ACR/EULAR SSc criteria. Patients were divided into two time periods: 2012-2017 and 2018-2022. We analysed the prescription patterns of endothelin receptor antagonists (ERA), phosphodiesterase type-5 inhibitors (PDE5i), calcium channel blockers (CCB), intravenous iloprost, and antiplatelet therapies. Logistic regression was used to evaluate temporal trends and interaction effects.</p><p><strong>Results: </strong>A total of 8079 patients were included. Significant increases over time were observed in the use of ERA (7% to 12%, P < 0.001), PDE5i (5.4% to 7.2%, P = 0.064), CCB (20% to 32%, P < 0.001) and anti-platelet therapies (15% to 20%, P < 0.001). There was a notable decrease in iloprost use (3.1% to 0.3%, P < 0.001). The prevalence of active digital ulcers (DU) decreased (16% to 13%, P = 0.040), while a history of DU (24% to 30%, P < 0.001) increased. Year-by-year and non-linear increases were noted for ERA and CCB whereas non-linear increase was observed for PDE5i. Year-by-year and non-linear decrease was observed for Iloprost prescription.</p><p><strong>Conclusion: </strong>A significant change has occurred over time in vascular medication use in SSc patients, with increased utilization of ERA, PDE5i, CCB and anti-platelet therapies suggesting the adoption of more proactive and/or preventive treatment strategies.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"5354-5363"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ankylosed posterior spinal structures: the catalyst for syndesmophytes growth and impaired spinal mobility in axial spondyloarthritis.","authors":"Simin Liao, Jian Zhu, Liuquan Cheng, Zheng Zhao, Gui Luo, Chuan Song, Jiaxin Zhang, Feng Huang","doi":"10.1093/rheumatology/keaf199","DOIUrl":"10.1093/rheumatology/keaf199","url":null,"abstract":"<p><strong>Objective: </strong>To identify risk factors for spinal structural progression and determine the most significant impact on syndesmophytes growth and impaired spinal mobility in axSpA.</p><p><strong>Methods: </strong>Baseline and 2-year follow-up clinical, thoracic and lumbar spine CT data of 94 patients were analysed. A vertebral syndesmophytes unit (VSU) was defined as syndesmophytes anterior to the vertebral body and its intervertebral disc space, with volumes calculated by Mimics software. Bilateral facet/costovertebral/costotransverse joints were assessed. Syndesmophytes growth was assessed with a linear mixed-effects model, and posterior spinal structures progression were evaluated with generalized linear mixed-effects models. Influence of spinal changes on BASMI-change was analysed with a generalized linear model. Conditional R2 values quantified model fit, with coefficient percentage representing each variable's contribution.</p><p><strong>Results: </strong>Syndesmophytes growth occurred in 44.99% of VSUs. Baseline facet joints ankylosis/erosion and costovertebral/costotransverse joints ankylosis were associated with syndesmophytes growth (P < 0.05). Contributing factors included changes of facet joints (56.84%), costotransverse joints (17.65%), costovertebral joints (16.26%) and age (6.08%). Structural progression was found in 8.79% (281/3196) of facet joints, among which 43.77% progressed to ankylosis, with age (6.56%) and baseline ankylosis/erosion (48.02%) driving this change. In addition, 16.31% of costovertebral joints progressed, with age (3.63%) and 2-year costotransverse lesions progression (12.30%) as significant predictors. And 2.07% of costotransverse joints progressed, with costovertebral lesions (25.61%) and age (0.81%) correlating significantly. Ankylosed costovertebral joints (25.10%), facet joints (16.86%), costotransverse joints (12.72%) and syndesmophytes growth (4.45%) significantly contribute to BASMI-change.</p><p><strong>Conclusions: </strong>Ankylosed posterior spinal structures emerged as the paramount driver of syndesmophytes growth and a critical impediment to spinal mobility in axSpA.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"5322-5329"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK inhibitors alleviate metabolic dysregulation, inflammation and fibrosis in osteoarthritis: insights from human joint cells and synovium.","authors":"Geneviève Paulissen, Olivier Malaise, Céline Deroyer, Edith Charlier, Sophie Neuville, Zelda Plener, Thierry Thirion, Christophe Daniel, Clio Ribbens, Dominique de Seny","doi":"10.1093/rheumatology/keaf298","DOIUrl":"10.1093/rheumatology/keaf298","url":null,"abstract":"<p><strong>Objectives: </strong>Osteoarthritis (OA) presents a significant clinical challenge due to its heterogeneous nature, characterized by cartilage degradation, inflammation and fibrosis. Current treatments offer limited efficacy, highlighting the need for novel therapeutic approaches. Our study aimed to investigate the effects of two Janus kinase (JAK) inhibitors, tofacitinib and baricitinib, on various hallmarks of OA in human joint cells and synovium.</p><p><strong>Methods: </strong>Human OA fibroblast-like synoviocytes (FLS), OA chondrocytes and synovial explants were cultured with tofacitinib or baricitinib, with or without additional stimulation (IL-1β or TGF-β). The levels of phosphorylated (p) signal transducer and activator of transcription (STAT) 1, p-STAT3, SOX9, and α-smooth muscle actin (α-SMA) were assessed by western blot and SOX9, COL2A1, ACAN, ACTA2, CTGF and COL3A1 gene expression was examined by RT-qPCR. Secreted IL-6, MMP-1, MMP-3 and MMP-13 were measured in supernatants by ELISA.</p><p><strong>Results: </strong>Tofacitinib or baricitinib increased the gene expression of anabolic factors SOX9, COL2A1, and ACAN while decreasing MMP-13 and MMP-3 levels in OA chondrocytes. Secreted levels of IL-6 and MMP-1 were significantly reduced in IL-1β-stimulated OA FLS and in OA synovial explants treated with tofacitinib or baricitinib. Finally, baricitinib decreased some fibrotic markers: α-SMA expression, ACTA2 gene expression, and CTGF levels in TGF-β-stimulated OA FLS.</p><p><strong>Conclusion: </strong>Tofacitinib and baricitinib modulate some features of OA pathophysiology by promoting anabolic processes in OA cartilage, reducing inflammation in OA synovium and attenuating some fibrotic factors in OA FLS. These findings demonstrate the potential use of tofacitinib and baricitinib as therapeutic options for managing OA, and highlight pathogenic pathways to target for further research and development of new OA treatment strategies.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"5539-5550"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of systemic lupus erythematosus onset in sisters with Lynch syndrome carrying MSH2 mutation.","authors":"Maaya Fukumura, Koji Kitagori, Tsuneo Sasai, Ryosuke Hiwa, Hideaki Tsuji, Mirei Shirakashi, Shuji Akizuki, Ran Nakashima, Hajime Yoshifuji, Akio Morinobu","doi":"10.1093/rheumatology/keaf310","DOIUrl":"10.1093/rheumatology/keaf310","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"5570-5572"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: LncRNA-H19 silencing suppresses synoviocytes proliferation and attenuates collagen-induced arthritis progression by modulating miR-124a.","authors":"","doi":"10.1093/rheumatology/keaf369","DOIUrl":"10.1093/rheumatology/keaf369","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"5562"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144966972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}